{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:40:50Z","timestamp":1793248850252,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Olav Thon Foundation, Ekhaga foundation, The Swedish Heart Lung Foundation"},{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Efficient high-throughput drug screening assays are necessary to enable the discovery of new anti-mycobacterial drugs. The purpose of our work was to develop and validate an assay based on live-cell imaging which can monitor the growth of two distinct phenotypes of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> and to test their susceptibility to commonly used TB drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Both planktonic and cording phenotypes were successfully monitored as fluorescent objects using the live-cell imaging system IncuCyte S3, allowing collection of data describing distinct characteristics of aggregate size and growth. The quantification of changes in total area of aggregates was used to define IC<jats:sub>50<\/jats:sub> and MIC values of selected TB drugs which revealed that the cording phenotype grew more rapidly and displayed a higher susceptibility to rifampicin. In checkerboard approach, testing pair-wise combinations of sub-inhibitory concentrations of drugs, rifampicin, linezolid and pretomanid demonstrated superior growth inhibition of cording phenotype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results emphasize the efficiency of using automated live-cell imaging and its potential in high-throughput whole-cell screening to evaluate existing and search for novel antimycobacterial drugs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12866-021-02212-3","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T07:03:08Z","timestamp":1622876588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A high-throughput screening assay based on automated microscopy for monitoring antibiotic susceptibility of Mycobacterium tuberculosis phenotypes"],"prefix":"10.1186","volume":"21","author":[{"given":"Sadaf","family":"Kalsum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmoy","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lerm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"issue":"13","key":"2212_CR1","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.1007\/s00253-020-10606-y","volume":"104","author":"AA Adeniji","year":"2020","unstructured":"Adeniji AA, Knoll KE, Loots DT. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus. Appl Microbiol Biotechnol. 2020;104(13):5633\u201362.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"11","key":"2212_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nri.2017.69","volume":"17","author":"AM Cadena","year":"2017","unstructured":"Cadena AM, Fortune SM, Flynn JL. Heterogeneity in tuberculosis. Nat Rev Immunol. 2017;17(11):691\u2013702.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2212_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1084\/jem.86.2.175","volume":"86","author":"G Middlebrook","year":"1947","unstructured":"Middlebrook G, Dubos RJ, Pierce C. Virulence and morphological characteristics of mammalian tubercle bacilli. J Exp Med. 1947;86(2):175\u201384.","journal-title":"J Exp Med"},{"issue":"1","key":"2212_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1574-6968.2006.00143.x","volume":"257","author":"L Hall-Stoodley","year":"2006","unstructured":"Hall-Stoodley L, Brun OS, Polshyna G, Barker LP. Mycobacterium marinum biofilm formation reveals cording morphology. FEMS Microbiol Lett. 2006;257(1):43\u20139.","journal-title":"FEMS Microbiol Lett"},{"issue":"7","key":"2212_CR5","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1128\/JB.01485-09","volume":"192","author":"E Julian","year":"2010","unstructured":"Julian E, Roldan M, Sanchez-Chardi A, Astola O, Agusti G, Luquin M. Microscopic cords, a virulence-related characteristic of Mycobacterium tuberculosis, are also present in nonpathogenic mycobacteria. J Bacteriol. 2010;192(7):1751\u201360.","journal-title":"J Bacteriol"},{"key":"2212_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fcimb.2017.00278","volume":"7","author":"S Kalsum","year":"2017","unstructured":"Kalsum S, Braian C, Koeken V, Raffetseder J, Lindroth M, van Crevel R, et al. The cording phenotype of Mycobacterium tuberculosis induces the formation of extracellular traps in human macrophages. Front Cell Infect Microbiol. 2017;7:278.","journal-title":"Front Cell Infect Microbiol."},{"key":"2212_CR7","doi-asserted-by":"crossref","unstructured":"Arias L, Cardona P, Catala M, Campo-Perez V, Prats C, Vilaplana C, et al. Cording Mycobacterium tuberculosis bacilli have a key role in the progression towards active tuberculosis, which is stopped by previous immune response. Microorganisms. 2020;8(2).","DOI":"10.3390\/microorganisms8020228"},{"key":"2212_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tube.2018.07.001","volume":"112","author":"EG Ufimtseva","year":"2018","unstructured":"Ufimtseva EG, Eremeeva NI, Petrunina EM, Umpeleva TV, Bayborodin SI, Vakhrusheva DV, et al. Mycobacterium tuberculosis cording in alveolar macrophages of patients with pulmonary tuberculosis is likely associated with increased mycobacterial virulence. Tuberculosis (Edinb). 2018;112:1\u201310.","journal-title":"Tuberculosis (Edinb)"},{"key":"2212_CR9","doi-asserted-by":"crossref","unstructured":"Lerner TR, Queval CJ, Lai RP, Russell MR, Fearns A, Greenwood DJ, et al. Mycobacterium tuberculosis cords within lymphatic endothelial cells to evade host immunity. JCI Insight. 2020;5(10).","DOI":"10.1172\/jci.insight.136937"},{"key":"2212_CR10","first-page":"463","volume":"8","author":"S Vijay","year":"2017","unstructured":"Vijay S, Nair RR, Sharan D, Jakkala K, Mukkayyan N, Swaminath S, et al. Mycobacterial cultures contain cell size and density specific sub-populations of cells with significant differential susceptibility to antibiotics, oxidative and nitrite stress. Front Microbiol. 2017;8:463.","journal-title":"Front Microbiol"},{"issue":"3","key":"2212_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/17460441.2020.1707801","volume":"15","author":"T Parish","year":"2020","unstructured":"Parish T. In vitro drug discovery models for Mycobacterium tuberculosis relevant for host infection. Expert Opin Drug Discov. 2020;15(3):349\u201358.","journal-title":"Expert Opin Drug Discov"},{"issue":"16","key":"2212_CR12","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1016\/j.bmc.2014.12.031","volume":"23","author":"UH Manjunatha","year":"2015","unstructured":"Manjunatha UH, Smith PW. Perspective: challenges and opportunities in TB drug discovery from phenotypic screening. Bioorg Med Chem. 2015;23(16):5087\u201397.","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"2212_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41429-019-0205-9","volume":"72","author":"EM Grzelak","year":"2019","unstructured":"Grzelak EM, Choules MP, Gao W, Cai G, Wan B, Wang Y, et al. Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening. J Antibiot (Tokyo). 2019;72(10):719\u201328.","journal-title":"J Antibiot (Tokyo)"},{"issue":"5707","key":"2212_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223\u20137.","journal-title":"Science"},{"issue":"2","key":"2212_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/jac\/dkr472","volume":"67","author":"N Andreu","year":"2012","unstructured":"Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother. 2012;67(2):404\u201314.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2212_CR16","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1371\/journal.pmed.0050075","volume":"5","author":"NJ Garton","year":"2008","unstructured":"Garton NJ, Waddell SJ, Sherratt AL, Lee SM, Smith RJ, Senner C, et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med. 2008;5(4):e75.","journal-title":"PLoS Med"},{"issue":"1","key":"2212_CR17","doi-asserted-by":"publisher","first-page":"e1006774","DOI":"10.1371\/journal.pcbi.1006774","volume":"15","author":"I Katzir","year":"2019","unstructured":"Katzir I, Cokol M, Aldridge BB, Alon U. Prediction of ultra-high-order antibiotic combinations based on pairwise interactions. PLoS Comput Biol. 2019;15(1):e1006774.","journal-title":"PLoS Comput Biol"},{"issue":"10","key":"2212_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/cyto.a.23129","volume":"91","author":"OR Song","year":"2017","unstructured":"Song OR, Deboosere N, Delorme V, Queval CJ, Deloison G, Werkmeister E, et al. Phenotypic assays for Mycobacterium tuberculosis infection. Cytometry A. 2017;91(10):983\u201394.","journal-title":"Cytometry A"},{"issue":"2","key":"2212_CR19","doi-asserted-by":"publisher","first-page":"e1003946","DOI":"10.1371\/journal.ppat.1003946","volume":"10","author":"SA Stanley","year":"2014","unstructured":"Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 2014;10(2):e1003946.","journal-title":"PLoS Pathog"},{"issue":"10","key":"2212_CR20","doi-asserted-by":"publisher","first-page":"e1000645","DOI":"10.1371\/journal.ppat.1000645","volume":"5","author":"T Christophe","year":"2009","unstructured":"Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, et al. High content screening identifies decaprenyl-phosphoribose 2\u2019 epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 2009;5(10):e1000645.","journal-title":"PLoS Pathog"},{"key":"2212_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2017.03.022","volume":"127","author":"AJ Manning","year":"2017","unstructured":"Manning AJ, Ovechkina Y, McGillivray A, Flint L, Roberts DM, Parish T. A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis. Methods. 2017;127:3\u201311.","journal-title":"Methods"},{"key":"2212_CR22","doi-asserted-by":"crossref","unstructured":"Queval CJ, Song OR, Delorme V, Iantomasi R, Veyron-Churlet R, Deboosere N, et al. A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput\/high-content screening. J Vis Exp. 2014\u00a0(83):e51114.","DOI":"10.3791\/51114"},{"issue":"9","key":"2212_CR23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nm.3262","volume":"19","author":"K Pethe","year":"2013","unstructured":"Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med. 2013;19(9):1157\u201360.","journal-title":"Nat Med"},{"key":"2212_CR24","doi-asserted-by":"crossref","unstructured":"Richter A, Shapira T, Av-Gay Y. THP-1 and dictyostelium infection models for screening and characterization of anti-mycobacterium abscessus hit compounds. Antimicrob Agents Chemother. 2019;64(1).","DOI":"10.1128\/AAC.01601-19"},{"key":"2212_CR25","doi-asserted-by":"publisher","first-page":"553962","DOI":"10.3389\/fmicb.2020.553962","volume":"11","author":"T Shapira","year":"2020","unstructured":"Shapira T, Rankine-Wilson L, Chao JD, Pichler V, Rens C, Pfeifer T, et al. High-content screening of eukaryotic kinase inhibitors Identify CHK2 inhibitor activity against mycobacterium tuberculosis. Front Microbiol. 2020;11:553962.","journal-title":"Front Microbiol"},{"issue":"2","key":"2212_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.chom.2013.01.008","volume":"13","author":"V Sundaramurthy","year":"2013","unstructured":"Sundaramurthy V, Barsacchi R, Samusik N, Marsico G, Gilleron J, Kalaidzidis I, et al. Integration of chemical and RNAi multiparametric profiles identifies triggers of intracellular mycobacterial killing. Cell Host Microbe. 2013;13(2):129\u201342.","journal-title":"Cell Host Microbe"},{"issue":"10","key":"2212_CR27","doi-asserted-by":"publisher","first-page":"E943-52","DOI":"10.1073\/pnas.1321390111","volume":"111","author":"A Bernut","year":"2014","unstructured":"Bernut A, Herrmann JL, Kissa K, Dubremetz JF, Gaillard JL, Lutfalla G, et al. Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation. Proc Natl Acad Sci U S A. 2014;111(10):E943-52.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2212_CR28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/infdis\/jiaa187","volume":"222","author":"MD Johansen","year":"2020","unstructured":"Johansen MD, Kremer L. Large extracellular cord formation in a zebrafish model of mycobacterium kansasii infection. J Infect Dis. 2020;222(6):1046\u201350.","journal-title":"J Infect Dis"},{"issue":"10","key":"2212_CR29","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1093\/jac\/dky268","volume":"73","author":"K Niward","year":"2018","unstructured":"Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlstrom O, Alomari T, et al. Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting. J Antimicrob Chemother. 2018;73(10):2838\u201345.","journal-title":"J Antimicrob Chemother"},{"key":"2212_CR30","unstructured":"Organization WH. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva;2021."},{"issue":"4","key":"2212_CR31","doi-asserted-by":"publisher","first-page":"e0153079","DOI":"10.1371\/journal.pone.0153079","volume":"11","author":"G Leisching","year":"2016","unstructured":"Leisching G, Pietersen RD, Mpongoshe V, van Heerden C, van Helden P, Wiid I, et al. The host response to a clinical MDR mycobacterial strain cultured in a detergent-free environment: a global transcriptomics approach. PLoS One. 2016;11(4):e0153079.","journal-title":"PLoS One"},{"issue":"4","key":"2212_CR32","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.medmal.2016.04.007","volume":"46","author":"N Lounis","year":"2016","unstructured":"Lounis N, Vranckx L, Gevers T, Kaniga K, Andries K. In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis. Med Mal Infect. 2016;46(4):220\u20135.","journal-title":"Med Mal Infect"},{"key":"2212_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.tube.2016.07.002","volume":"100","author":"G Leisching","year":"2016","unstructured":"Leisching G, Pietersen RD, Wiid I, Baker B. Virulence, biochemistry, morphology and host-interacting properties of detergent-free cultured mycobacteria: an update. Tuberculosis (Edinb). 2016;100:53\u201360.","journal-title":"Tuberculosis (Edinb)"},{"issue":"10","key":"2212_CR34","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1111\/bcp.14048","volume":"85","author":"RJ Svensson","year":"2019","unstructured":"Svensson RJ, Niward K, Davies Forsman L, Bruchfeld J, Paues J, Eliasson E, et al. Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis. Br J Clin Pharmacol. 2019;85(10):2341\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2212_CR35","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/jac\/dkp262","volume":"64","author":"T Schon","year":"2009","unstructured":"Schon T, Jureen P, Giske CG, Chryssanthou E, Sturegard E, Werngren J, et al. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother. 2009;64(4):786\u201393.","journal-title":"J Antimicrob Chemother"},{"issue":"1\u20132","key":"2212_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tube.2003.08.003","volume":"84","author":"JE Gomez","year":"2004","unstructured":"Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb). 2004;84(1\u20132):29\u201344.","journal-title":"Tuberculosis (Edinb)"},{"key":"2212_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jep.2014.09.020","volume":"157","author":"N Abuzeid","year":"2014","unstructured":"Abuzeid N, Kalsum S, Koshy RJ, Larsson M, Glader M, Andersson H, et al. Antimycobacterial activity of selected medicinal plants traditionally used in Sudan to treat infectious diseases. J Ethnopharmacol. 2014;157:134\u20139.","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"2212_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1128\/CVI.00446-09","volume":"17","author":"D Eklund","year":"2010","unstructured":"Eklund D, Welin A, Schon T, Stendahl O, Huygen K, Lerm M. Validation of a medium-throughput method for evaluation of intracellular growth of Mycobacterium tuberculosis. Clin Vaccine Immunol. 2010;17(4):513\u20137.","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"2212_CR39","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1046\/j.1365-2672.2000.01017.x","volume":"88","author":"RJ Lambert","year":"2000","unstructured":"Lambert RJ, Pearson J. Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values. J Appl Microbiol. 2000;88(5):784\u201390.","journal-title":"J Appl Microbiol"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-021-02212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-021-02212-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-021-02212-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T19:03:15Z","timestamp":1622919795000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-021-02212-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2212"],"URL":"https:\/\/doi.org\/10.1186\/s12866-021-02212-3","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}